Johnson and Johnson Innovation JJDC, Inc., Novartis Institutes for BioMedical Research, and Osage University Partners also participated in the round along with Vor Co-founder PureTech Health.
Vor said it plans to use the proceeds from the financing to advance its lead HSC-based candidate for the treatment of acute myeloid leukemia towards the clinic, and to further build its pipeline to treat hematologic malignancies.
The company's engineered HSC technology platform is designed to address fundamental limitations of current immunotherapies.
Vor's approach has the potential to expand the reach of targeted immunotherapies to a broad range of patient populations and hematological malignancies by enabling new dosing paradigms for cancer-targeted immunotherapies, which can substantially improve the therapeutic window for efficacy and improve patient safety.
Co-founded by PureTech Health (LSE: PRTC) and based on the pioneering work of Siddhartha Mukherjee, M.D., D.Phil, as well as Vor's own intellectual property, Vor is developing a proprietary pipeline of best-in-class immunotherapies for patients.
The company is working with some of the world's leading oncologists and immunologists including Hans-Peter Kiem, M.D., Ph.D., the Fred Hutch Endowed chair for Cell and Gene Therapy and the director of the Stem Cell and Gene Therapy Program at the Fred Hutchinson Cancer Research Center and a Professor of Medicine at the University of Washington School of Medicine; Dan Littman, M.D., Ph.D., the Kimmel Professor of Molecular Immunology at the Skirball Institute and an Investigator of the Howard Hughes Medical Institute at NYU Langone Health; Derrick J. Rossi, Ph.D., an Associate Professor in the Stem Cell and Regenerative Biology Department at Harvard Medical School and Harvard University; and Joseph Bolen, Ph.D., chief scientific officer at PureTech Health.
Sumitomo Pharma Canada announces ORGOVYX (relugolix) prostate cancer drug availability in Canada
Rigel Pharmaceuticals names new executive vice president and chief medical officer
MaaT Pharma to present MaaT013 Early Access Program results at EBMT 2024
Dassault Systèmes and CDR-Life partner to boost cancer therapy innovation
Merck finalises acquisition of Harpoon Therapeutics Inc
Celltrion USA submits CT-P39 Biologics License Application to FDA